Call 408.493.1800 | Fax 408.493.1801 | Toll Free 800.891.9699 (US Only) | Email: [email protected]


An apoptosis inducer and a mouse STING ligand
Catalog #: 2804
SKU-Size Size Price Qty
2804-5 5 mg
2804-25 25 mg
More Sizes Get Quote

Product Details

Alternate Name 2-(5,6-dimethyl-9-oxoxanthen-4-yl)acetic acid; Vadimezan; ASA404
Appearance White solid
CAS # 117570-53-3
Molecular Formula C₁₇H₁₄O₄
Molecular Weight 282.29
Purity ≥98% by HPLC
Solubility DMSO (>10 mg/ml)
SMILES CC1=C(C2=C(C=C1)C(=O)C3=C(O2)C(=CC=C3)CC(=O)O)C
InChi InChI=1S/C17H14O4/c1-9-6-7-13-15(20)12-5-3-4-11(8-14(18)19)17(12)21-16(13)10(9)2/h3-7H,8H2,1-2H3,(H,18,19)
PubChem CID 123964
MDL Number MFCD00870555
Handling Protect from air and light
Storage Conditions -20°C
Shipping Conditions Gel Pack
USAGE For Research Use Only! Not For Use in Humans.


DMXAA acts as a tumor vascular disrupting agent, inducing apoptosis in tumor vascular endothelium resulting in necrosis at the tumor core. It potently activates the TANK-binding kinase 1-interferon regulatory factor 3 signaling pathway in leukocytes, inducing type-I-interferon production. In addition, DMXAA significantly inhibits several kinases in endothelial cells, including the vascular endothelial growth factor (VEGF) receptors VEGFR1 and VEGFR2 (IC₅₀ = 119 and 11 µM, respectively). Recent studies have shown that DMXAA is a competitive agonist ligand for mouse.

Why buy BioVision Products?
Global Presence
Technical Support
BioVision aims to provide our customers innovative tools for accelerating drug discovery and biological research. BioVision offers >8,000 products including the most comprehensive array of assay kits for key targets in Metabolic pathways.
BioVision is committed to providing the highest quality products at a competitive price.
We have a broad network of global distributors who are ready to address your research needs and ensure fast delivery.
Our highly trained Technical Support team provides comprehensive product support and is dedicated to resolving your issues quickly and efficiently.